We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

18 hedge funds and large institutions have $2.3M invested in Moleculin Biotech in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

24% more capital invested

Capital invested by funds: $1.85M → $2.3M (+$449K)

6% more funds holding

Funds holding: 17 → 18 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
18
Holders Change
+1
Holders Change %
+5.88%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$209K
2
BlackRock
BlackRock
New York
+$90.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$73.7K
4
CIBC World Market
CIBC World Market
Ontario, Canada
+$53.2K
5
TSS
Two Sigma Securities
New York
+$24.6K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$24K
2
Wells Fargo
Wells Fargo
California
-$9K
3
ACS
Archford Capital Strategies
Illinois
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.18M +$209K +51 +21%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$226K +$73.7K +18 +47%
WIC
3
Whitegate Investment Counselors
New Hampshire
$174K – – –
CIBC World Market
4
CIBC World Market
Ontario, Canada
$170K +$53.2K +13 +45%
Truist Financial
5
Truist Financial
North Carolina
$161K – – –
BlackRock
6
BlackRock
New York
$89K +$90.1K +22 New
Bank of America
7
Bank of America
North Carolina
$45K – – –
Northern Trust
8
Northern Trust
Illinois
$41K +$16.4K +4 +67%
Commonwealth Equity Services
9
Commonwealth Equity Services
Massachusetts
$39K +$12.3K +3 +43%
LNWWM
10
Laird Norton Wetherby Wealth Management
California
$35K – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$31K +$12.3K +3 +60%
TSS
12
Two Sigma Securities
New York
$24K +$24.6K +6 New
RJFSA
13
Raymond James Financial Services Advisors
Florida
$23K – – –
Morgan Stanley
14
Morgan Stanley
New York
$22K +$4.09K +1 +20%
PNC Financial Services Group
15
PNC Financial Services Group
Pennsylvania
$14K – – –
CF
16
Centaurus Financial
California
$13K +$12.3K +3 New
OIA
17
OneDigital Investment Advisors
Kansas
$5K – – –
APA
18
American Portfolios Advisors
New York
$2.69K +$4.09K +1 New
GRP
19
Global Retirement Partners
California
$1K – – –
VF
20
Virtu Financial
New York
– -$24K -6 Closed
Wells Fargo
21
Wells Fargo
California
– -$9K -2 Closed
ACS
22
Archford Capital Strategies
Illinois
– -$6K -1 Closed

MBRX Hedge Fund Activity: Q2 2018 in Review

18 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2018, worth a combined $2.3M — up 24% from $1.85M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MBRX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, adding an estimated $209K. The largest seller was Virtu Financial, exiting entirely with an estimated $24K sold.

  • 18 institutional investors held Moleculin Biotech (MBRX) as of Q2 2018, up from 17 in Q1 2018.
  • Funds reported $2.3M of Moleculin Biotech stock for Q2 2018, up 24% quarter-over-quarter.
  • 4 funds opened new Moleculin Biotech positions in Q2 2018 and 3 closed out, a net change of +1 holder.
  • The largest Moleculin Biotech buyer in Q2 2018 was Vanguard Group, an estimated $209K added.
  • The largest Moleculin Biotech seller in Q2 2018 was Virtu Financial, an estimated $24K sold.

Based on aggregated 13F filings for Q2 2018.